drugset / Trial / NCT02521233
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
Timeline
- Start
- 2016-11
- Primary completion
- 2017-05
- Completion
- 2017-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Candesartan | Unknown | 8 mg | Oral |
| Subject | Chlorthalidone | Other / unclassified | 12.5 mg | Oral |
| Subject | Chlorthalidone | Other / unclassified | 25 mg | Oral |
| Comparator | Hydrochlorothiazide | Unknown | 12.5 mg | Oral |
| Comparator | Losartan | Other / unclassified | 50 mg | Oral |